Compare KIDS & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KIDS | TECX |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 588.8M | 618.9M |
| IPO Year | 2016 | 2018 |
| Metric | KIDS | TECX |
|---|---|---|
| Price | $21.97 | $20.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $27.22 | ★ $71.00 |
| AVG Volume (30 Days) | 170.1K | ★ 230.8K |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,049,000.00 | N/A |
| Revenue This Year | $12.96 | N/A |
| Revenue Next Year | $11.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.95 | N/A |
| 52 Week Low | $14.42 | $15.60 |
| 52 Week High | $26.74 | $39.53 |
| Indicator | KIDS | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 28.86 |
| Support Level | $21.13 | $20.52 |
| Resistance Level | $23.31 | $23.61 |
| Average True Range (ATR) | 0.76 | 1.17 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 41.98 | 14.18 |
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.